AstraZeneca plans to build a next-generation active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin, Ireland.
The new plant will allow for late-stage development and early commercial supply, adopting the latest process technology and digital innovations to deliver medicines to patients.
The $360 million investment at the Alexion Campus in College Park, Dublin, is expected to create about 100 skilled direct jobs, including scientists and engineers. The project was developed with the support and collaboration of Ireland’s investment agency, IDA Ireland.
Pascal Soriot, CEO of AstraZeneca, said: “This is a tremendously proud moment for us all at AstraZeneca and I am delighted that we are bringing this very significant investment to Dublin, which, with the support of the IDA, will create highly skilled jobs, nurture the country’s dynamic life sciences sector and allow for the development of high value-added medicines.”
The investment program is expected to significantly reduce commercialization lead times and costs and introduce more sustainable manufacturing processes. The design of the plant will permit the manufacturing of a wide range of medicines.
AstraZeneca operates a manufacturing and logistics site near Newark and employs about 1,500 in northern Delaware.
Earlier, ILC Dover, Newark, a maker of spacesuits and containment systems for drug manufacturing, announced plans for a site in Ireland.